STOCK TITAN

Cue Health Inc - HLTH STOCK NEWS

Welcome to our dedicated news page for Cue Health (Ticker: HLTH), a resource for investors and traders seeking the latest updates and insights on Cue Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cue Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cue Health's position in the market.

Rhea-AI Summary
Cue Health Inc. (HLTH) appoints Clint Sever as CEO and adds Dr. Paul Brown and Dr. Lisa Danzig as strategic advisors to enhance business operations and commercialization efforts. The company aims to review its business strategy and cost structure for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
none
-
Rhea-AI Summary
Cue Health Inc. reports $18.8 million in Q4 revenue and $70.9 million in full-year 2023 revenue. The company submitted clinical data for RSV and Flu A/B tests to the FDA. Cue is in late-stage development of Herpes + Mpox Multiplex Molecular Test. They executed cost reduction plans saving $200 million annually. Fourth quarter revenue breakdown shows private sector revenue at $17.0 million and public sector revenue at $1.8 million. Cue reported a GAAP net loss of $148.4 million in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.14%
Tags
-
Rhea-AI Summary
Cue Health Inc. (HLTH) will announce its Q4 and full-year 2023 financial results on March 13, 2024. The company will host a conference call and webcast to discuss the results and recent highlights. Participants can register in advance for the call and access it via telephone or webinar.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.9%
Tags
Rhea-AI Summary
Cue Health (HLTH) partners with Tarsadia Investments and appoints Rishi Reddy to its Board of Directors. The company aims to enhance shareholder value and improve operational efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Cue Health, a healthcare technology company (Nasdaq: HLTH), will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
conferences
-
Rhea-AI Summary
HLTH - Cue Health Inc. Reports Impressive Q3 2023 Financial Results, Revenue Exceeds Expectations, Plans for New Multiplex Molecular Test Development, and Achieves Cost Savings. Revenue of $17.5 million, 50% above guidance range. Three tests in review with the FDA. Annualized run rate cost savings of approximately $165 million. Net change in cash for the quarter was $(17.1) million. Ended the third quarter with cash and cash equivalents of $111.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
Rhea-AI Summary
Cue Health Inc. will release its Q3 2023 financial results on November 8, 2023. A conference call and webcast will be held to discuss the results and recent highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
-
Rhea-AI Summary
Cue Health stockholders call for Board to cut expenditures and focus on core business
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Cue Health's molecular COVID-19 test demonstrated 99.4% accuracy compared to lab-based PCR in a clinical study on asymptomatic people. The test provides fast results in 20 minutes and has 100% clinical sensitivity to detect positive cases. The study also showed high test sensitivity (98.7%) for detection at varying stages of infection and viral load. Cue's test offers critical benefits such as reducing the likelihood of spread, facilitating earlier access to treatment, and maintaining cost-effectiveness. Cue recently received FDA approval for its COVID-19 test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
covid-19
Rhea-AI Summary
Cue Health adopts shareholder rights plan to protect long-term value, responding to significant third-party share accumulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
none
Cue Health Inc

Nasdaq:HLTH

HLTH Rankings

HLTH Stock Data

25.77M
97.10M
12.83%
47.89%
0.36%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
San Diego

About HLTH

cue, a revolutionary device for tracking health information at the molecular level. for the first time, consumers can track 5 key health and lifestyle indicators: inflammation, vitamin d, fertility, influenza, and testosterone in just minutes, at home. cue sends the data via bluetooth 4.0 to the user's smartphone, where the free cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level. by simply adding a noninvasive droplet of saliva, blood, or nasal swab, you can access deep information about your body only previously available from a lab -- on demand and on your schedule. interactive charts put you in touch with your health, making it easy to discover new trends, monitor your progress, and share it with the people who matter most. cue also features life feed, an incredible new smartphone-based way to visualize the daily effect of activity, food, and sleep on your molecular health. cue makes research-based recommendations for foods proven to sup